Quantellect · Analysts · Analyst Profile
Analyst rating accuracy & track record
Michael Freeman does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 DYNDyne Therapeutics Inc | Buy | $37.00 | Jun 2025 | +9.5% | Miss |
 IRONDisc Medicine Inc. | Buy | $89.00 | Jun 2025 | +14.5% | Hit |
 TECXTectonic Therapeutic, Inc. | Buy | $76.00 | Jun 2025 | +16.1% | Miss |
 WVEWave Life Sciences Ltd | Buy | $14.00 | Jun 2025 | −33.9% | Hit |
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.